Abstract
Positron emission tomography (PET) is used in an increasing number of patients for the evaluation of solitary pulmonary nodes as well as for staging and restaging of lung cancer. It adds metabolic information to the anatomical images of CT and may lead to significant cost savings as well in primary diagnostics as in restaging if patients are carefully selected.
MeSH terms
-
Carcinoma, Bronchogenic / diagnostic imaging*
-
Carcinoma, Bronchogenic / economics
-
Carcinoma, Bronchogenic / pathology
-
Carcinoma, Bronchogenic / therapy
-
Carcinoma, Non-Small-Cell Lung / diagnostic imaging
-
Carcinoma, Non-Small-Cell Lung / economics
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Carcinoma, Non-Small-Cell Lung / therapy
-
Carcinoma, Small Cell / diagnostic imaging
-
Carcinoma, Small Cell / economics
-
Carcinoma, Small Cell / pathology
-
Carcinoma, Small Cell / therapy
-
Cost-Benefit Analysis
-
Fluorodeoxyglucose F18*
-
Humans
-
Lung Neoplasms / diagnostic imaging*
-
Lung Neoplasms / economics
-
Lung Neoplasms / pathology
-
Lung Neoplasms / therapy
-
Lymphatic Metastasis / diagnostic imaging
-
Lymphatic Metastasis / pathology
-
Neoplasm Staging
-
Sensitivity and Specificity
-
Tomography, Emission-Computed* / economics